|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In immune competent mice, the ibrutinib-sorafenib combination reduced the numbers of BTK+ immune cells in the tumor microenvironment.
|
31582534 |
2020 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The Ivy GBM database was then utilized to determine the intratumoral spatial localization of BTK activity by investigating the expression of BTK-related transcription factors (TFs) within tumors.
|
31628288 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Therapeutic targeting of sIgM function via ibrutinib, an inhibitor of Bruton tyrosine kinase (BTK), causes inhibition and tumor cell redistribution into the blood, with significant clinical benefit.
|
30373751 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We found that inhibition of BTK leads to suppression of tumor growth, which was mediated via potent suppression of AKT/mTOR, apoptosis, and metabolic stress.
|
30413649 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
RNA-seq analysis revealed that ARQ531 constrained tumor cell proliferation and survival through Bruton's tyrosine kinase and transcriptional program dysregulation, with proteasome-mediated MYB degradation and depletion of short-lived proteins that are crucial for tumor growth and survival, including ERK, MYC and MCL1.
|
31624110 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In lymphomas resistant to BTK inhibition, we show that blocking BTK activity enhanced tumor dependencies from alternative oncogenic signals downstream of the BCR, converging on MYC upregulation.
|
29567799 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
By integrating the genomic features of oesophageal tumour cell lines with siRNA and drug screening data, we identified a series of candidate targets in oesophageal cancer, including a sensitivity to inhibition of the kinase BTK in <i>MYC</i> amplified oesophageal tumour cell lines.
|
28830912 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
While it has long been considered oncogenic in the context of B cell malignancies, recent data shows that BTK can also act as a tumour suppressor in other cells, as an essential member of the p53 and p73 responses to damage.
|
30337526 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry was used to detect the Btk expression in kidney from LN patients and tumor surrounding tissues.
|
28612243 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.
|
29455639 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Bruton's tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms.
|
27697038 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Taken together, these results suggest that the encouraging therapeutic efficacy of Btk inhibitor may be due to both direct cytotoxic effects on malignant B cells and immunomodulatory effects on macrophages present in the tumor microenvironment.
|
28424405 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
<i>In vitro</i> studies support the effectiveness of combing PI3Kδ and BTK inhibitors.<b>Experimental Design:</b> As CLL proliferation and survival depends on the microenvironment, we used murine models to assess the efficacy of the BTK inhibitor acalabrutinib combined with the PI3Kδ inhibitor ACP-319 <i>in vivo</i> We compared single-agent with combination therapy in TCL1-192 cell-injected mice, a model of aggressive CLL.<b>Results:</b> We found significantly larger reductions in tumor burden in the peripheral blood and spleen of combination-treated mice.
|
28645939 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Significant tumor regression was observed with a combination of PI3Kδ and Bruton's tyrosine kinase inhibitors in the mouse TMD8 xenograft.
|
28178345 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
BTK expression in B-cell neoplasms was similar to that of normal B-cell lymphocytes.
|
28028621 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
|
28265007 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Finally, we found that KS99 inhibits the in vivo tumor growth of MM cells through the inhibition of BTK and tubulin.
|
28647392 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Recently, some preclinical data have demonstrated that BTK is present in certain tumor subtypes and in other relevant cells that are contributing to the tumor microenvironment such as dendritic cells, macrophages, myeloid derived suppressor cells and endothelial cells.
|
28641100 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In conclusion, BCR signaling, activated in the lymph node microenvironment in vivo, appears to promote tumor proliferation and survival and may explain the sensitivity of this lymphoma to BTK inhibitors.
|
27127301 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The irreversible Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma.
|
26627823 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Bruton's tyrosine kinase (BTK) is a critical mediator of survival in B-cell neoplasms.
|
27756747 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Furthermore, overexpression of BTK in myeloma cells promoted tumor growth in laboratory mice and rendered side population-derived tumors that contained high levels of BTK more sensitive to the selective, second-generation BTK inhibitor, CGI1746, than side population-derived tumors that harbored low levels of BTK.
|
25589346 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Pharmacological inhibition with ibrutinib of Bruton's tyrosine kinase, a kinase that is required for BCR signaling to engage NF-κB, is selectively toxic for ABC DLBCL tumors; a finding that has now been translated to the clinic.
|
25805587 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
We find that BTK is expressed in prostate cells, with the alternate BTK-C isoform predominantly expressed in prostate cancer cells and tumors.
|
26383180 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Simultaneous inhibition of BTK and mTOR causes apoptosis both in vitro and in vivo and results in tumor regression in a xenograft model.
|
24970801 |
2014 |